Silence Therapeutics And Quark Pharmaceuticals Expand Strategic Licensing Agreement
London, England and Freemont, CA. July 31, 2007 – Silence Therapeutics plc and Quark Pharmaceuticals, Inc. (“Quark”), announced today an expansion of their current strategic technology licensing agreement. In April 2005 the Companies signed an Option and Licence Agreement, which provided Quark with access to Silence Therapeutics’ novel proprietary siRNA technology, AtuRNAi. The first outcome